<DOC>
	<DOC>NCT00511472</DOC>
	<brief_summary>A study to assess safety, pharmacokinetics (PK), and pharmacodynamics (PD) of MK-0941 in Type 2 diabetics being treated with basal insulin.</brief_summary>
	<brief_title>An Investigational Drug Study in Adults With Type 2 Diabetes on Basal Insulin (MK-0941-006)</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Male or female (of nonchildbearing potential) between 18 to 70 years of age Diagnosed with Type 2 Diabetes and currently being treated with basal insulin Smokers may participate, but they are limited to 10 cigarettes per day while at the clinic and must follow clinic smoking rules History of Type 1 diabetes Treated with peroxisome proliferatoractivated receptor (PPAR) agonists within 12 weeks prior to study start History of severe hypoglycemia Allergic to insulin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>